$NOVN #Novartis AG NOVARTIS: Novartis in oncology: an under-appreciated upside? | BUY | CHF105(+31%): NOVARTIS - BUY | CHF105(+31%) Novartis in oncology: an under-appreciated upside? Kisqali and Piqray are existing assets with new avenues… https://t.co/0zlJf9pPEz #equity #stocks